Drug-coated Balloon Angioplasty Versus Drug-eluting Stenting for Femoropopliteal Arterial Disease: A Review of the Current Status

Doo Sun Sim, MD, PhD1,2, Myung Ho Jeong, MD, PhD1, Youngkeun Ahn, MD, PhD1, Carlos Mena-Hurtado, MD, PhD3, John Martin, MD, PhD4, and Anthony Mathur MD, PhD2,5*

1Department of Cardiovascular Medicine, Chonnam National University Hospital, Chonnam National University School of Medicine, Gwangju, Republic of Korea.

2Centre for Cardiovascular Medicine and Devices, William Harvey Research Institute, Queen Mary University of London, London, UK.

3Yale Vascular Outcomes Program, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, Connecticut, USA.

4Division of Medicine, University College London, London, UK.

5Department of Cardiology, Barts Heart Centre, Barts Health NHS Trust, London, UK.


ABSTRACT

Endovascular procedures are frequently performed for symptomatic femoropopliteal disease. Drug-eluting stents (DES) and drug-coated balloons (DCB) were introduced to improve long-term outcomes and demonstrated superior outcomes to percutaneous transluminal angioplasty in randomised clinical trials. Femoropopliteal disease, however, can be challenging to treat using an endovascular approach as this segment suffers increased biomechanical stress during extremity movements, which may lead to chronic vascular injury or even stent fracture. The advantages of DCB include the direct and homogeneous delivery of an antiproliferative agent to the arterial wall, and the ability to reach tortuous and longer lesions without a vascular implant; however, the lack of scaffold makes the intervention prone to significant recoil. Even though the use of DCB, a leave-nothing-behind strategy, may appear desirable, the need for bailout stenting will increase as lesions become more complex. This review summarises and compares the currently available evidence regarding the use of DCB and DES in the treatment of femoropopliteal disease.

Keywords
Balloon angioplasty, Drug-eluting stents, Endovascular procedures, Peripheral arterial disease.

Introduction
Atherosclerotic peripheral arterial disease (PAD) commonly involves the superficial femoral artery (SFA) and the popliteal artery (PA), and it is becoming increasingly prevalent [1]. Endovascular procedures are widely accepted as the first line of treatment for symptomatic PAD [2]. The 2017 European Society of Cardiology and European Society for Vascular Surgery guidelines on the treatment of PAD recommend an endovascular treatment as a class I indication in symptomatic femoropopliteal PAD with short (<25 cm) lesions [3], whereas the 2016 American College of Cardiology/American Heart Association guidelines give a class IIa recommendation for endovascular therapy in patients with femoropopliteal disease [4].

Percutaneous transluminal angioplasty (PTA) in the femoropopliteal segment is associated with high rates of restenosis ranging from 40% to 50% within 1 year [5], limiting its use to very short lesions [6]. Previous trials using self-expanding, flexible nitinol stents
suggested that stenting is more beneficial in longer femoropopliteal segments, compared to PTA alone [6–8]. However, bare-metal stents (BMS) were still associated with 30% to 40% restenosis within 2 to 3 years of implantation due to neointimal hyperplasia, causing in-stent restenosis (ISR) [9]. In order to overcome the limitations of both PTA and BMS, drug-based strategies such as drug-eluting stents (DES) and drug-coated balloons (DCB) were introduced to improve long-term outcomes [10]. DES and DCB have both demonstrated superior outcomes to PTA alone in randomised clinical trials (RCTs) [5,11-18]. Femoropopliteal disease, however, can be challenging to treat using an endovascular approach as this segment suffers increased biomechanical stress from repetitive deformations during extremity movements, which may lead to chronic vascular injury or even stent fracture [19]. The advantages of DCB include the direct and homogeneous delivery of an antiproliferative agent to the arterial wall without a vascular implant, and the ability to reach tortuous and longer lesions that would otherwise require multiple overlapping stents [20]. On the other hand, the lack of scaffold makes the intervention prone to significant recoil. This review summarises and compares the currently available evidence regarding the use of DCB and DES for the treatment of femoropopliteal disease.

### Clinical Trials Comparing Drug-Based Strategies and PTA DES versus PTA

Table 1 details the DES trials for femoropopliteal disease included in this review. Currently, two self-expanding paclitaxel DES have received CE mark approval for use in patients with femoropopliteal disease. The Zilver PTX (Cook Corporation, Bloomington, IN, USA) is a nitinol self-expanding polymer-free stent coated with paclitaxel. In the Zilver PTX (Evaluation of the Zilver PTX Drug-Eluting Stent in the Above the Knee Femoropopliteal Artery) RCT, SFA lesions treated with the Zilver PTX stent had a superior 12-month patency rate compared to PTA (83.1% vs

<table>
<thead>
<tr>
<th>Trial Name, n</th>
<th>Inclusion Criteria</th>
<th>Lesion length</th>
<th>DES</th>
<th>Company</th>
<th>Drug, Dose</th>
<th>Coating polymer</th>
<th>Control</th>
<th>Outcome (DES vs Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zilver PTX 2011 [11] n=474</td>
<td>Symptomatic de novo or nonstented restenotic lesions in SFA or PA</td>
<td>DES 66.4 ± 38.9 mm PTA 63.1 ± 40.7 mm</td>
<td>Zilver PTX nitinol DES (n=236)</td>
<td>Cook Medical, Bloomington, IN, USA</td>
<td>Paclitaxel, 3 µg/mm²</td>
<td>Polymer-free</td>
<td>PTA (n=238)</td>
<td>1-yr PP: 83.1% vs 32.8% (p&lt;0.001) 1-yr CD-TLR: 9.5% vs 17.5% (p=0.01) 5-yr PP: 66.4% vs 43.4% (p&lt;0.01) 5-yr freedom from CD-TLR: 83.1% vs 67.6% (p&lt;0.01)</td>
</tr>
<tr>
<td>MAJESTIC 2016 [21] n=57</td>
<td>Symptomatic de novo or nonstented restenotic lesions in SFA or PA</td>
<td>DES 70.8 ± 28.1 mm</td>
<td>Eluvia nitinol DES (n=57)</td>
<td>Boston Scientific, Marlborough, MA, USA</td>
<td>Paclitaxel, 0.167 µg/mm²</td>
<td>None</td>
<td>None</td>
<td>1-yr PP: 96.4% 2-yr PP: 83.5% 3-yr freedom from TLR: 85.3%</td>
</tr>
<tr>
<td>IMPERIAL 2018 [23] n=465</td>
<td>Symptomatic de novo or nonstented restenotic lesions in SFA or PA</td>
<td>Eluvia 86.5 ± 36.9 mm</td>
<td>Eluvia nitinol DES (n=309)</td>
<td>Boston Scientific, Marlborough, MA, USA</td>
<td>Paclitaxel, 0.167 µg/mm²</td>
<td>Primer polymer: poly(n-butyl methacrylate) Active polymer: PVDF-HFP</td>
<td>Zilver PTX nitinol DES (n=156)</td>
<td>1-yr PP: 86.8% in Eluvia vs 81.5% in Zilver PTX (non-inferiority p&lt;0.0001) 1-yr freedom from MAE: 94.9% in Eluvia vs 91.0% in Zilver PTX (non-inferiority p=0.0001)</td>
</tr>
<tr>
<td>SIROCCO 2006 [24] n=93</td>
<td>Symptomatic de novo or nonstented restenotic lesions in SFA</td>
<td>DES 85 ± 44 mm BMS 81 ± 52 mm</td>
<td>SMART nitinol DES (n=47)</td>
<td>Cordis Corp., Warren, NJ, USA</td>
<td>Sirolimus, 0.9 µg/mm²</td>
<td>Not specified</td>
<td>BMS (n=46)</td>
<td>2-yr ISR: 22.9% vs 21.1% (p=1.0) 2-yr freedom from TLR: 92.8% vs 83.8% (p=0.30)</td>
</tr>
<tr>
<td>Zilver PTX 2011 [11] n=120</td>
<td>Symptomatic de novo or nonstented restenotic lesions in SFA or PA. A total of 120 patients with acute PTA failure were included out of 238 patients allocated to PTA</td>
<td>Not available</td>
<td>Provisional Zilver PTX nitinol DES (n=61)</td>
<td>Cook Medical, Bloomington, IN, USA</td>
<td>Paclitaxel, 3 µg/mm²</td>
<td>Polymer-free</td>
<td>Provisional BMS (n=59)</td>
<td>1-yr PP: 89.9% vs 73.0% (p=0.01) 5-yr PP: 72.4% vs 53.0% (p=0.03) 5-yr freedom from CD-TLR: 84.9% vs 71.6% (p=0.06)</td>
</tr>
<tr>
<td>BATTLE 2020 [25] n=181</td>
<td>Symptomatic de novo stenosis of SFA or PA</td>
<td>DES 69 ± 35 mm BMS 76 ± 41 mm</td>
<td>Zilver PTX nitinol DES (n=90)</td>
<td>Cook Medical, Bloomington, IN, USA</td>
<td>Paclitaxel, 3 µg/mm²</td>
<td>Polymer-free</td>
<td>BMS (n=91)</td>
<td>1-yr freedom from ISR: 91.9% vs 86.6% (p=0.64) 2-yr PP: 78.8% vs 74.6% (p=0.62) 2-yr TLR: 12.4% vs 14.4% (p=0.69)</td>
</tr>
</tbody>
</table>

BMS, bare-metal stent; CD-TLR, clinically driven target lesion revascularisation; DES, drug-eluting stent; ISR, in-stent restenosis; MAE, major adverse event rate (defined as all causes of death through 1 month, major amputation of the target limb through 12 months, or CD-TLR through 12 months); PA, popliteal artery; PP, primary patency; PVDF-HFP, poly(vinylidene fluoride-co-hexafluoropropylene); PTA, percutaneous transluminal angioplasty; TLR, target lesion revascularisation.
Table 2: Trials of DCB versus PTA for femoropopliteal disease.

<table>
<thead>
<tr>
<th>Trial Name, n</th>
<th>Inclusion criteria</th>
<th>Lesion length</th>
<th>DCB</th>
<th>Company</th>
<th>Drug, Dose</th>
<th>Coating technology</th>
<th>Control</th>
<th>Outcome (DCB vs Control)</th>
</tr>
</thead>
<tbody>
<tr>
<td>THUNDER 2008 [13] n=154</td>
<td>Symptomatic de novo stenosis, restenosis, or ISR in SFA or PA</td>
<td>DCB 75 ± 62 mm PTA 74 ± 67 mm PTA + PIC 74 ± 65 mm</td>
<td>DCB (n=48)</td>
<td>Paclitaxel, 3.0 µg/mm²</td>
<td>Paclapath® technology (excipient: iopromide)</td>
<td>PTA (n=54), PTA + PIC (n=52)</td>
<td>6-month LLL: DCB 0.4 ± 1.2 mm vs PTA 1.7 ± 1.8 mm vs PTA + PIC 2.2 ± 1.6 mm (p=0.001 for DCB vs PTA) 2-year TLR: DCB 52% vs PTA 15% vs PTA + PIC 40% (p=0.001 for DCB vs PTA)</td>
<td></td>
</tr>
<tr>
<td>FemPac 2008 [14] n=87</td>
<td>Symptomatic de novo stenosis, restenosis, or ISR in SFA or PA</td>
<td>DCB 40 (21-61) mm PTA 47 (27-85) mm</td>
<td>DCB (n=45)</td>
<td>Paclitaxel, 3.0 µg/mm²</td>
<td>Paclapath® technology (excipient: iopromide)</td>
<td>PTA (n=42)</td>
<td>6-month LLL: 0.5 ± 1.1 mm vs 1.0 ± 1.1 mm (p=0.03) 6-month TLR: 7% vs 33% (p=0.002)</td>
<td></td>
</tr>
<tr>
<td>PACIFIER 2012 [15] n=91</td>
<td>Symptomatic de novo stenosis, restenosis, or ISR in SFA or PA</td>
<td>DCB 70 ± 53 mm PTA 66 ± 55 mm</td>
<td>DCB (n=42)</td>
<td>Paclitaxel, 3.0 µg/mm²</td>
<td>FreePac™ hydrophilic coating (excipient: urea)</td>
<td>PTA (n=47)</td>
<td>6-month LLL: -0.01 mm (95% CI, -0.29 to 0.26) vs 0.65 mm (95% CI 0.37 to -0.93) (p=0.001) 1-year CD-TLR: 7.1% vs 27.9% (p&lt;0.02)</td>
<td></td>
</tr>
<tr>
<td>DEBATE SFA 2013 [16] n=104</td>
<td>Symptomatic de novo stenosis in SFA or PA</td>
<td>DCB + BMS 94 ± 60 mm PTA + BMS 96 ± 69 mm</td>
<td>IN.PACT Admiral DCB (n=53)</td>
<td>Medtronic Vascular, Santa Rosa, CA, USA</td>
<td>Paclitaxel, 3.0 µg/mm²</td>
<td>FreePac™ hydrophilic coating (excipient: urea)</td>
<td>PTA + BMS (n=51)</td>
<td>1-year binary restenosis: 17% vs 47.3% (p&lt;0.008) 1-year freedom from CD-TLR: 83% vs 66.7% (p=0.07)</td>
</tr>
<tr>
<td>IN.PACT SFA 2015 [15] 2018 [26] n=331</td>
<td>Symptomatic de novo or non-stented restenotic lesions in SFA or PA</td>
<td>DCB 88.1 ± 51.2 mm PTA 89.4 ± 48.9 mm</td>
<td>IN.PACT Admiral DCB (n=220)</td>
<td>Medtronic Vascular, Santa Rosa, CA, USA</td>
<td>Paclitaxel, 3.5 µg/mm²</td>
<td>FreePac™ hydrophilic coating (excipient: urea)</td>
<td>PTA (n=111)</td>
<td>1-year PP: 82.2% vs 52.4% (p&lt;0.001) 1-year CD-TLR: 2.4% vs 20.6% (p&lt;0.001) 3-year PP: 69.5% vs 45.1% (p&lt;0.001) 3-year CD-TLR: 15.2% vs 31.1% (p=0.002)</td>
</tr>
<tr>
<td>LEVANT II 2015 [17] n=476</td>
<td>Symptomatic de novo or non-stented restenotic lesions in SFA or PA</td>
<td>DCB 62.7 ± 41.4 mm PTA 63.2 ± 40.4 mm</td>
<td>Luxtron DCB (n=316)</td>
<td>Bard, New Hope, MN, USA</td>
<td>Paclitaxel, 2.0 µg/mm²</td>
<td>Bard-specific coating (excipient: polysorbate and sorbitol)</td>
<td>PTA (n=160)</td>
<td>1-year PP: 65.2% vs 52.6% (p=0.02) 1-year freedom from CD-TLR: 12.3% vs 16.8% (p=0.21)</td>
</tr>
<tr>
<td>BIOLUX P 1 2015 [27] n=60</td>
<td>Symptomatic de novo or non-stented restenotic lesions in SFA or PA</td>
<td>DCB 68.5 ± 57.0 mm PTA 51.4 ± 47.2 mm</td>
<td>Passeo-18 Lux DCB (n=30)</td>
<td>Biotronik AG, Buelach, Switzerland</td>
<td>Paclitaxel, 3.0 µg/mm²</td>
<td>Exciplent: butyryl-tr-n-hexyl citrate</td>
<td>PTA (n=30)</td>
<td>6-month LLL: 0.51 ± 0.72 mm vs 1.04 ± 1.00 mm (p=0.03) 1-year CD-TLR: 15.4% vs 41.7% (p=0.06)</td>
</tr>
<tr>
<td>ILLUMENATE EU RCT 2018 [18] n=294</td>
<td>Symptomatic de novo or restenotic lesions in SFA or PA</td>
<td>DCB 72 ± 52 mm PTA 71 ± 53 mm</td>
<td>TransPax™ (n=222)</td>
<td>Philips, Amsterdam, the Netherlands</td>
<td>Paclitaxel, 2.0 µg/mm²</td>
<td>EnduraCoat™ technology (excipient: polyethylene glycol)</td>
<td>PTA (n=72)</td>
<td>2-year PP: 75.9% vs 61.0% (p=0.03) 2-year CD-TLR: 12.1% vs 30.5% (p=0.001)</td>
</tr>
<tr>
<td>RANGER SFA 2018 [28] n=105</td>
<td>Symptomatic de novo or non-stented restenotic lesions in SFA or PA</td>
<td>DCB 68 ± 46 mm PTA 60 ± 48 mm</td>
<td>Ranger DCB (n=71)</td>
<td>Boston Scientific, MA, USA</td>
<td>Paclitaxel, 2.0 µg/mm²</td>
<td>TransPax™ coating technology (excipient: acetyl tributyl citrate)</td>
<td>PTA (n=34)</td>
<td>1-year PP: 86.4% vs 56.5% (p=0.001) 1-year freedom from TLR: 91.2% vs 69.9% (p=0.01)</td>
</tr>
<tr>
<td>EFFPAC 2020 [29] n=171</td>
<td>Symptomatic de novo or non-stented restenotic lesions in SFA or PA</td>
<td>DCB 59.1 ± 43.4 mm PTA 55.8 ± 39.1 mm</td>
<td>Limonor DCB (n=85)</td>
<td>iVascular, Barcelona, Spain</td>
<td>Paclitaxel, 3.0 µg/mm²</td>
<td>TransferTec™ coating technology (excipient: organic ester)</td>
<td>PTA (n=86)</td>
<td>2-year PP: 90.2% vs 67.2% (p=0.001) 2-year freedom from TLR: 97.2% vs 78.0% (p=0.001)</td>
</tr>
<tr>
<td>FAIR 2015 [30] n=119</td>
<td>Symptomatic SFA ISR</td>
<td>DCB 82.3 ± 70.9 mm PTA 81.1 ± 66.2 mm</td>
<td>IN.PACT Admiral DCB (n=62)</td>
<td>Medtronic Vascular, Santa Rosa, CA, USA</td>
<td>Paclitaxel, 3.5 µg/mm²</td>
<td>FreePac™ hydrophilic coating (excipient: urea)</td>
<td>PTA (n=57)</td>
<td>6-month recurrent in-stent restenosis: 15.4% vs 44.7% (p=0.002) 1-year freedom from CD-TLR: 90.8% vs 52.6% (p=0.0001)</td>
</tr>
<tr>
<td>ISAR-PEBIS 2017 [31] n=70</td>
<td>Symptomatic SFA ISR</td>
<td>DCB 132 ± 65 mm PTA 146 ± 69 mm</td>
<td>IN.PACT Admiral DCB (n=36)</td>
<td>Medtronic Vascular, Santa Rosa, CA, USA</td>
<td>Paclitaxel, 3.5 µg/mm²</td>
<td>FreePac™ hydrophilic coating (excipient: urea)</td>
<td>PTA (n=34)</td>
<td>6- to 8-month percentage diameter stenosis: 44 ± 33% vs 65 ± 33% (p=0.01) 2-year CD-TLR: 19% vs 50% (p&lt;0.007)</td>
</tr>
<tr>
<td>PACUBA 2016 [32] n=74</td>
<td>Symptomatic ISR in SFA or PA</td>
<td>DCB 173 ± 113 mm PTA 184 ± 88 mm</td>
<td>FREEWAY DCB (n=35)</td>
<td>Eurocor Tec GmbH, Bonn, Germany</td>
<td>Paclitaxel, 3.0 µg/mm²</td>
<td>Excipient: shellac (aleuritic and shellotic acid)</td>
<td>PTA (n=39)</td>
<td>1-year PP: 40.7% vs 13.4% (p&lt;0.02) 1-year freedom from CD-TLR: 49.0% vs 22.1% (p=0.11)</td>
</tr>
</tbody>
</table>

CD-TLR, clinically driven target lesion revascularisation; CI, confidence interval; DCB, drug-coated balloon; EU RCT, European Randomised Clinical Trial; ISR, in-stent restenosis; LLL, late lumen loss; PA, popliteal artery; PIC, paclitaxel in contrast medium; PP, primary patency; PTA, percutaneous transluminal angioplasty; SFA, superficial femoral artery; TLR, target lesion revascularisation.
Lutonix DCB (Bard, New Hope, Minnesota, USA) was associated in the Prevention of Femoropopliteal Restenosis (PAS-18) study, the use of DES versus PTA prior to BMS at 12 months reduced restenosis (17% vs 52.6%, p=0.02), compared with PTA [17]. BIOLUX P-I (A Prospective, Multi-center, Randomised Controlled, First in Man Study to Assess the Safety and Performance of the PAS-18 Lux Paclitaxel Releasing PTA Balloon Catheter vs the Uncoated Passeo-18 Balloon Catheter in Patients with Stenosis and Occlusion of the Femoropopliteal Arteries) evaluated the efficacy of the PAS-18 Lux DCB (Biotronik AG, Buelach, Switzerland) in comparison with PTA in 60 patients. Late lumen loss at 6 months (0.51 ± 0.72 mm vs 1.04 ± 1.00 mm, p=0.03) and CD-TLR at 12 months (15.4% vs 41.7%, p=0.06) were lower in DCB group [27]. In the ILLUMINATE European Randomised Clinical Trial, the Stellarex DCB (Philips, Amsterdam, the Netherlands), composed of a low dose of paclitaxel (2 mg/mm²), was compared to PTA in 294 patients with femoropopliteal disease [18]. The DCB group showed higher primary patency at 2 years (75.9% vs 61.0%, p=0.03) and a lower rate of CD-TLR, compared with the PTA group (12.1% vs 30.5%, p<0.001). In the RANGER SFA trial, the Ranger DCB (Boston Scientific, MA, USA) showed higher primary patency (86.4% vs 56.5%, p<0.001) and freedom from TLR (91.2% vs 69.9%, p<0.01) at 1 year, compared to PTA [28]. Similarly, in the EFFPAC trial, the Luminor DCB (iVascular, Barcelona, Spain) was associated with higher primary patency (90.2% vs 62.7%, p<0.001) and freedom from TLR (97.2% vs 78%, p=0.001) at 2-year follow-up [29].

Several RCTs explored the outcome of DCB for the treatment of femoropopliteal ISR [30-32]. The FAIR (Femoral Artery In-Stent Restenosis) study randomised 119 patients with symptomatic SFA ISR to either IN.PACT Admiral DCB or PTA. The primary endpoint of recurrent ISR at 6 months was significantly lower in the DCB group compared to the PTA group (15.4% vs 44.7%, p=0.002). Freedom from TLR was higher with DCB compared to PTA at 12 months (90.8% vs 52.6%, p<0.001) [30]. The ISAR-PEBIS (Paclitaxel-Eluting Balloon Versus Conventional Balloon Angioplasty for In-Stent Restenosis of Superficial Femoral Artery) trial compared angioplasty using IN.PACT Admiral DCB and standard PTA in 70 patients with SFA ISR [31]. The DCB group had significant reduction in percentage diameter stenosis at 6 to 8 months (44 ± 33% vs 65 ± 33%, p=0.01) and in CD-TLR at 24 months (19% vs 50%, p=0.007), compared to the PTA group. In the PACUBA (Paclitaxel Balloon Versus Standard Balloon in In-Stent Restenoses of the Superficial Femoral Artery) trial of angioplasty using FREEWAY DCB (Eurocor Tech GmbH, Bonn, Germany) versus PTA in 74 patients with femoropopliteal ISR [32], DCB angioplasty was associated with higher rates of primary patency (40.7% vs 13.4%, p=0.02) and freedom from CD-TLR (49.0% vs 22.1%, p=0.11) at 12 months, compared to PTA. A meta-analysis of patient-level data from these 3 RCTs (FAIR [30], ISAR-PEBIS [31], and PACUBA [32]) has recently been published [33]. Patients treated with DCB angioplasty exhibited a lower risk for CD-TLR (hazard ratio [HR] 0.25, 95% confidence interval [CI] 0.14–0.46, p<0.001) and recurrent ISR (HR 0.19, 95% CI 0.10–0.35, p<0.001) at 12-month follow-up. While this data suggests the superior efficacy of DCB over PTA, there are encouraging data comparing DCB to standard PTA or other devices in the treatment of femoropopliteal ISR.

### DES vs BMS

Data comparing DES and BMS for femoropopliteal lesions is scarce and conflicting (Table 1). The SIROCCO (Sirolimus Coated Cordis Nitinol Self-Expandable Stent for Treatment of Obstructive Superficial Femoral Artery Disease) trial did not demonstrate better results with sirolimus-eluting stents compared to BMS [24]. In the Zilver PTX trial, patients who were randomised to PTA and had suboptimal results were then randomised to provisional DES vs BMS. The DES group had improved 5-year primary patency and freedom from CD-TLR [12]. In contrast, in the recent BATTLE (Bare Metal Stent Versus Paclitaxel Eluting Stent) RCT, the Zilver PTX DES failed to prove superiority over BMS in freedom from ISR at 1 year or in primary patency or TLR through 2 years [25].

### DCB versus PTA

Clinical trials comparing DCB and PTA for femoropopliteal disease are summarised in Table 2. Early RCTs, THUNDER (Local Taxane with Short Exposure for Reduction of Restenosis in Distal Arteries), FemPac (Femoral Paclitaxel), and PACIFIER (Paclitaxel-coated Balloons in Femoral Indication to Defeat Restenosis) showed superiority of DCB over PTA in femoropopliteal disease [13-15].

In the IN.PACT SFA (Randomised Trial of IN.PACT Admiral Drug Coated Balloon vs Standard PTA for the Treatment of SFA and Proximal Popliteal Arterial Disease) study, IN.PACT Admiral DCB (Medtronic Vascular, Santa Rosa, CA, USA) significantly improved 12-month primary patency compared to PTA (82.2% vs 52.4%, p<0.001), with sustained benefit at 3 years (69.5% vs 45.1%, p<0.001) [5,26]. The DEBATE-SFA (Drug Eluting Balloon in Peripheral Intervention for the Superficial Femoral Artery) trial evaluated a strategy using DCB predilation followed by BMS placement. The use of IN.PACT Admiral DCB prior to BMS implantation was associated with lower restenosis (17% vs 47.3%, p=0.008) and higher rates of freedom from CD-TLR (83% vs 66.7%, p=0.07) compared to PTA prior to BMS at 12 months [16]. In the LEVANT 2 (Lutonix Paclitaxel-Coated Balloon for the Prevention of Femoropopliteal Restenosis) study, the use of Lutonix DCB (Bard, New Hope, Minnesota, USA) was associated with significantly improved 12-month primary patency (65.2% vs 52.6%, p=0.02), compared with PTA [17].
Table 3: Trials of DCB versus DES for femoropopliteal disease.

<table>
<thead>
<tr>
<th>Trial Name, n</th>
<th>Inclusion Criteria</th>
<th>Mean Lesion Length</th>
<th>DCB</th>
<th>DES</th>
<th>Outcome (DCB vs DES)</th>
</tr>
</thead>
<tbody>
<tr>
<td>REAL PTX 2019 [35] n=150</td>
<td>Symptomatic de novo or non-stented restenotic lesions in SFA or PA</td>
<td>DCB 149.7 ± 87.4 mm DES 155.5 ± 89.4 mm</td>
<td>IN.PACT Admiral or IN.PACT Pacific or Lutonix DCB (n=75)</td>
<td>Zilver PTX DES (n=75)</td>
<td>1-yr PP: 80% vs 79% (p=0.96) 3-yr PP: 38% vs 54% (p=0.02) 1-yr freedom from CD-TLR: 92.5% vs 90.0% (p=0.34) 3-yr freedom from CD-TLR: 71.3% vs 68.9% (p=0.74)</td>
</tr>
<tr>
<td>DRASTICO 2019 [36] n=192</td>
<td>Symptomatic de novo or non-stented lesions in SFA or PA</td>
<td>DCB 146.3 ± 96.4 mm DES 140.7 ± 86.7 mm</td>
<td>IN.PACT Pacific DCB + provisional BMS (n=96)</td>
<td>Zilver PTX DES (n=96)</td>
<td>1-yr restenosis: 22% vs 21% (p=0.90) 1-yr CD-TLR: 14% vs 17% (p=0.50)</td>
</tr>
</tbody>
</table>

BMS: Bare-Metal Stent; CD-TLR: Clinically Driven Target Lesion Revascularization; DCB: Drug-Coated Balloon; DES: Drug-Eluting Stent; PA: Popliteal Artery; PP: Primary Patency.

up to 1 year, there is still a need for further investigation into the long-term durability of DCB angioplasty in this setting.

DCB versus DES

Recent RCTs of DCB versus DES are summarised in Table 3. In a retrospective study of DCB and DES outcomes in 228 patients, restenosis and clinical outcomes were not significantly different at 1 year. Binary restenosis rates were 23.9% and 30.4% and CD-TLR rates were 15.6% and 19.0% in the DCB and DES groups, respectively [34]. The REAL PTX (Randomised Evaluation of the Zilver PTX Stent vs Paclitaxel-Eluting Balloons for Treatment of Symptomatic Peripheral Artery Disease of the Femoropopliteal Artery) study randomised 150 patients with femoropopliteal disease to either DCB with bailout stenting or DES. Patency rates were similar between DCB and DES (80% vs 79%, p=0.96) at 1 year but reduced to 38% and 54% at 3 years (p=0.02). Freedom from CD-TLR was high in both groups at 1 year (DCB 92.5% vs DES 90.0%, p=0.34) but decreased in both groups at 3 years (DCB 71.3% vs DES 68.9%, p=0.74) [35]. The DRASTICO (Drug-eluting balloon versus drug-eluting stent for Complex Femoropopliteal Arterial Lesions) study compared the use of DCB and DES in 192 patients randomised to paclitaxel DCB with bailout nitinol BMS or to paclitaxel DES. There was no significant difference between the two groups in target-lesion binary restenosis at 1 year (DCB 22% vs DES 21%) [36].

Discussion

The advent of drug-based strategies utilising DES and DCB has significantly reduced the restenosis and CD-TLR in patients with femoropopliteal disease. However, most of the evidence has been derived from relatively simple lesions and there is a paucity of data regarding complex, long or calcified disease. Even though stenting improved the outcome in intermediate- to long-length lesions compared to PTA, the risk of late complications such as ISR or stent fracture remains. DCB is associated with improved vessel patency and reduced stent use, but they frequently entail bailout stenting, particularly in complex lesions such as heavy calcification, chronic and long chronic total occlusions (CTO).

DCB in clinical practice

Currently, most DCB are coated with paclitaxel at a concentration between 2 and 3.5 μg/mm² [17,18,26]. Paclitaxel is often used for DCB coating due to its lipophilic properties and resistance to oxidation. Three DCB are in clinical use for femoropopliteal disease: Lutonix (Bard Lutonix, New Hope, Minnesota, USA), IN.PACT (Medtronic Vascular, Santa Rosa, California, USA), and Stellarex (Royal Philips, Amsterdam, The Netherlands). These DCB use polysorbate and sorbitol, urea, and polyethylene glycol as excipients, respectively. These excipients are coated onto the balloon with paclitaxel to control the release of the drug into the arterial wall [37].

There are a number of technical challenges in the development of DCB including effective transfer of drug to the vessel wall, minimising the loss of drug during the catheter advancement and providing a long-term anti-restenosis effect. Clinical trials have revealed that the use of DCB was associated with superior patency rates to PTA at 1 year [5,17]. However, patency rates decreased significantly beyond the first year, suggesting a late catch-up phenomenon following DCB treatment [26]. Similarly, in the REAL PTX trial [35], although the patency and CD-TLR rates were not different between DCB and DES at 1 year, there was a trend in favour of DES at long-term follow-up with a higher 3-year patency rate with DES than DCB (56.7% vs 42.4%, p=0.17) [35]. Furthermore, there has been concern over the reduced efficacy of DCB in long, complex lesions including heavy calcification [38]. The usage of adjunctive technologies such as atherectomy to debulk the plaque prior to DCB has been suggested to improve results [39]. Large-scale studies with long-term follow-up are warranted to evaluate the efficacy and safety of DCB in these lesions, which often require bailout stenting.

In deciding between DCB and DES for the treatment of femoropopliteal lesions, current evidence suggests stratified strategies according to the lesion complexity; with DCB for short- or intermediate-length, non-CTO lesions and DES for long, heavily calcified or CTO lesions. Consensus statements have been published to help guide these decisions [40]. However, a great deal of variation in practice remains an issue, which warrants clarification with further confirmatory RCTs. Until then a reasonable approach could be to observe the vessel response after pre-dilatation with PTA with a view to using DCB in lesions without dissection or residual stenosis and to using DES in those with suboptimal results or in long, calcified lesions.
Concern over paclitaxel-coated devices

Recently, the safety of paclitaxel-based therapies in patients with PAD has been called into question. A systematic review and study-level meta-analysis suggested an increased risk for late mortality in patients treated with paclitaxel DCB and DES [41]. The study reviewed 28 RCTs (n=4,663) of paclitaxel DCB and DES in femoropopliteal arteries. There was no difference in mortality at 1 year. However, there was a higher risk of all-cause mortality at 2 years compared with controls (7.2% vs 3.8%, risk ratio [RR] 1.68, 95% CI 1.15-2.47). All-cause mortality at 5 years was also higher with the paclitaxel-coated devices (14.7% vs 8.1%, RR 1.93, 95% CI 1.27-2.93). A subsequent meta-analysis of individual patient-level data from 8 RCTs of US Food and Drug Administration (FDA)–approved paclitaxel-coated balloons (IN.PACT Admiral, Lutonix, Stellarex) and stents (Zilver PTX) observed a 4.6% increase in absolute risk of death associated with the use of paclitaxel-coated devices compared with PTA at a median 4-year follow-up [42]. With the recovery of lost-to-follow-up data, the mortality risk was slightly attenuated but still significantly higher for paclitaxel-coated devices compared with PTA (HR 1.27, 95% CI 1.03-1.58). The US FDA has recommended that paclitaxel-coated devices should be reserved for patients at the highest risk of restenosis and alternative treatment options should be considered until the safety of these devices can be verified [43]. The potential increased mortality, however, should be interpreted with caution due to the substantial limitations of these meta-analyses such as pooling of studies of different paclitaxel-coated devices, missing study data, lack of dose-response relationships, and no known mechanism for the increased mortality [44].

Recent large randomised and observational studies [45-48], and long-term follow-up data from the RCTs [49-51] have refuted the increased mortality signal observed in patients treated with paclitaxel-coated devices. In the SWEDEPAD (Swedish Drug Elution Trial in Peripheral Arterial Disease) RCT (n=2,289), all-cause mortality was similar between the paclitaxel-coated and uncoated device groups at a mean follow-up of 2.5 years (drug-coated device: 25.5% vs uncoated device: 24.6%) [45]. In a retrospective analysis of the German BARMER insurance claims (n=37,914), the use of paclitaxel-coated balloons and stents were associated with improved survival at 5 years compared with uncoated devices (HR 0.83, 95% CI 0.77-0.90 in patients with chronic limb threatening ischaemia and HR 0.88, 95% CI 0.80-0.98 in patients with intermittent claudication) [46]. Another study from the same database (n=64,771) showed no evidence for increased mortality associated with paclitaxel-coated devices for over 11 years [47]. In an analysis from the Society for Vascular Quality Initiative Registry (n=8,376), mortality was overall similar between paclitaxel-coated balloon and PTA cohorts (9.6% vs 12.6%, p=0.14) and between paclitaxel-coated stent and BMS cohorts (8.8% vs 9.8%, p=0.75) at a median follow-up of 12.6 months and 13.0 months, respectively [48]. Long-term follow-up results from RCTs have also not shown an increased mortality signal. In a patient-level meta-analysis of IN.PACT trials comprised of 2 RCTs (IN.PACT SFA and IN.PACT SFA Japan) and 2 prospective single-arm studies (IN.PACT SFA China, IN.PACT Global) (n=1,980), there was no significant difference in all-cause mortality between DCB and PTA through 5 years (15.12% DCB vs 11.15% PTA) [49]. An analysis of individual patient-level data from the LEVANT trials (n=1,343) consisting of 3 RCTs (LEVANT 1, LEVANT 2, and LEVANT Japan Clinical Trial and a single arm continued-access arm of LEVANT 2) demonstrated no increase in mortality with the use of DCB compared to PTA at 5 years [50]. Analyses of the Zilver PTX patient-level data (n=479) showed no difference in all-cause mortality between DES and PTA/BMS cohorts through 5 years (19.1% vs 17.1%, p = 0.60) [51].

Future Directions

There has been great interest in ‘limus’ compounds as a potential substitute for paclitaxel in the DCB and DES arena [52]. These have broader therapeutic window [53] and may have an advantage over paclitaxel in safety outcomes. The SELUTION DCB is the first-in-human study (NCT02941224) currently underway of a sirolimus-coated balloon [SELUTION™ (MA Med Alliance SA, Mont-sur-Rolle, Switzerland)] in femoropopliteal disease. Recently, there have been efforts to improve stent designs by applying interwoven nitinol mesh, helical flow, and high flexibility in order to enhance long-term patency and reduce the risk of stent fracture [54-56]. Their utility as a DES platform or in adjunct to DCB should be validated in future studies. Furthermore, bioreosorbable vascular scaffolds hold promise as another initiative within the leave-nothing-behind strategy, even though there is room for improvement regarding the maintenance of mechanical integrity and optimal resorption [57].

Conclusions

In patients with atherosclerotic femoropopliteal disease, DCB and DES provide clear benefits over PTA and recent studies indicate that both of these drug-based approaches may be effective with comparable outcomes up to 1 year. Even though a leave-nothing-behind strategy with the use of DCB may appear desirable, the need for bailout stenting will increase as lesions become more complex. Further RCTs will be needed to assess long-term outcomes of DCB in comparison with DES. Until then, lesion characteristics alongside vessel response to PTA should help guide the decision on the optimal drug-based endovascular treatment strategy for this patient population.

References


© 2022 Sim DS, et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.